CA2175457A1 - Treatment for rheumatoid arthritis - Google Patents

Treatment for rheumatoid arthritis

Info

Publication number: CA2175457A1
Authority: CA; Canada
Prior art keywords: crf; days; administration; patient; treatment
Prior art date: 1993-11-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002175457A

Other languages

English (en)

French (fr)

Inventor

Irwin A. Braude

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Neurobiological Technologies Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-11-02

Filing date

1994-11-02

Publication date

1995-05-11

1994-11-02 Application filed by Individual filed Critical Individual

1995-05-11 Publication of CA2175457A1 publication Critical patent/CA2175457A1/en

Status Abandoned legal-status Critical Current

Links

206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 12
238000011282 treatment Methods 0.000 title claims description 30
230000002757 inflammatory effect Effects 0.000 claims abstract description 15
230000001667 episodic effect Effects 0.000 claims abstract description 13
230000001684 chronic effect Effects 0.000 claims abstract description 12
230000010398 acute inflammatory response Effects 0.000 claims abstract description 5
206010003246 arthritis Diseases 0.000 claims description 29
238000000034 method Methods 0.000 claims description 15
230000037396 body weight Effects 0.000 claims description 7
238000002347 injection Methods 0.000 claims description 7
239000007924 injection Substances 0.000 claims description 7
206010061218 Inflammation Diseases 0.000 claims description 5
230000004054 inflammatory process Effects 0.000 claims description 5
150000003839 salts Chemical group 0.000 claims description 5
208000038016 acute inflammation Diseases 0.000 claims description 4
230000006022 acute inflammation Effects 0.000 claims description 4
238000001990 intravenous administration Methods 0.000 claims description 3
238000007920 subcutaneous administration Methods 0.000 claims description 3
238000007913 intrathecal administration Methods 0.000 claims description 2
238000010521 absorption reaction Methods 0.000 claims 1
239000002765 corticotropin releasing factor derivative Substances 0.000 claims 1
238000001802 infusion Methods 0.000 claims 1
238000007910 systemic administration Methods 0.000 claims 1
230000000699 topical effect Effects 0.000 claims 1
102100021752 Corticoliberin Human genes 0.000 abstract description 52
239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract description 52
201000010099 disease Diseases 0.000 abstract description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 23
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 abstract description 6
230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
208000017667 Chronic Disease Diseases 0.000 abstract 1
101710113174 Corticoliberin Proteins 0.000 description 42
230000008961 swelling Effects 0.000 description 22
210000000548 hind-foot Anatomy 0.000 description 18
241000700159 Rattus Species 0.000 description 17
210000002683 foot Anatomy 0.000 description 16
241001465754 Metazoa Species 0.000 description 13
241000186359 Mycobacterium Species 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 10
230000001154 acute effect Effects 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 6
230000006698 induction Effects 0.000 description 6
101000895481 Homo sapiens Corticoliberin Proteins 0.000 description 5
KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
101000895537 Ovis aries Corticoliberin Proteins 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
238000010171 animal model Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000012085 chronic inflammatory response Effects 0.000 description 4
GBONBLHJMVUBSJ-FAUHKOHMSA-N corticorelin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)C1=CNC=N1 GBONBLHJMVUBSJ-FAUHKOHMSA-N 0.000 description 4
238000005259 measurement Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
241000283707 Capra Species 0.000 description 3
102400000739 Corticotropin Human genes 0.000 description 3
101800000414 Corticotropin Proteins 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
101000895495 Rattus norvegicus Corticoliberin Proteins 0.000 description 3
108010011107 Urotensins Proteins 0.000 description 3
102000026557 Urotensins Human genes 0.000 description 3
229960001230 asparagine Drugs 0.000 description 3
235000009582 asparagine Nutrition 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
229960000258 corticotropin Drugs 0.000 description 3
230000028709 inflammatory response Effects 0.000 description 3
230000000770 proinflammatory effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
239000000780 urotensin Substances 0.000 description 3
241000272517 Anseriformes Species 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
241000252169 Catostomus commersonii Species 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
241000252233 Cyprinus carpio Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
201000001263 Psoriatic Arthritis Diseases 0.000 description 2
208000036824 Psoriatic arthropathy Diseases 0.000 description 2
208000033464 Reiter syndrome Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
KFUIXDNQSMKKJQ-ZLFMSJRASA-N chembl439883 Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)CNC(=O)[C@H]2NC(=O)CC2)CCC1 KFUIXDNQSMKKJQ-ZLFMSJRASA-N 0.000 description 2
229940041967 corticotropin-releasing hormone Drugs 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000002267 hypothalamic effect Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
AOCUKGFDRUSDQH-PIKKTMSISA-N ocrf Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)CC)[C@@H](C)O)C(C)C)C(C)O)C1=CNC=N1 AOCUKGFDRUSDQH-PIKKTMSISA-N 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
208000002574 reactive arthritis Diseases 0.000 description 2
108010086511 sauvagine Proteins 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
101000895475 Bos taurus Corticoliberin Proteins 0.000 description 1
OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
208000014311 Cushing syndrome Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
206010061619 Deformity Diseases 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
OBSIQMZKFXFYLV-QMMMGPOBSA-N L-phenylalanine amide Chemical compound NC(=O)[C@@H](N)CC1=CC=CC=C1 OBSIQMZKFXFYLV-QMMMGPOBSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
241000220317 Rosa Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
-1 hydrobro-20 mide Chemical compound 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
238000011694 lewis rat Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
201000009395 primary hyperaldosteronism Diseases 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229940086735 succinate Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Rheumatology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002175457A 1993-11-02 1994-11-02 Treatment for rheumatoid arthritis Abandoned CA2175457A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US14652093A	1993-11-02	1993-11-02
US08/146,520		1993-11-02

Publications (1)

Publication Number	Publication Date
CA2175457A1 true CA2175457A1 (en)	1995-05-11

Family

ID=22517765

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002175457A Abandoned CA2175457A1 (en)	1993-11-02	1994-11-02	Treatment for rheumatoid arthritis

Country Status (10)

Country	Link
EP (1)	EP0726780A1 (cs)
JP (1)	JPH09504792A (cs)
AU (1)	AU8131694A (cs)
CA (1)	CA2175457A1 (cs)
CZ (1)	CZ122696A3 (cs)
HU (1)	HUT74275A (cs)
LT (1)	LT96079A (cs)
NO (1)	NO961747L (cs)
PL (1)	PL314191A1 (cs)
WO (1)	WO1995012416A1 (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6060288A (en) *	1994-08-03	2000-05-09	Mosaic Technologies	Method for performing amplification of nucleic acid on supports
US5780431A (en) *	1996-09-20	1998-07-14	Neurobiological Technologies, Inc.	Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
JP2002503954A (ja)	1997-04-01	2002-02-05	グラクソ、グループ、リミテッド	核酸増幅法
AR031640A1 (es)	2000-12-08	2003-09-24	Applied Research Systems	Amplificacion isotermica de acidos nucleicos en un soporte solido
EP1565436B1 (en) *	2002-11-27	2012-04-25	Incyte Corporation	3-aminopyrrolidine derivatives as modulators of chemokine receptors
WO2008093098A2 (en)	2007-02-02	2008-08-07	Illumina Cambridge Limited	Methods for indexing samples and sequencing multiple nucleotide templates
WO2010038042A1 (en)	2008-10-02	2010-04-08	Illumina Cambridge Ltd.	Nucleic acid sample enrichment for sequencing applications
US8182994B2 (en)	2009-09-15	2012-05-22	Illumina Cambridge Limited	Centroid markers for image analysis of high denisty clusters in complex polynucleotide sequencing
DE102011100783A1 (de)	2011-05-06	2012-11-08	Rolls-Royce Deutschland Ltd & Co Kg	Gasturbinenauswuchtvorrichtung
CN115137809A (zh) *	2021-03-31	2022-10-04	张菁	含有促肾上腺皮质激素及其衍生物的药物及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5006330A (en) *	1988-11-30	1991-04-09	The United States Of America As Represented By The Of The Department Of Health And Human Services	Evaluative means for detecting inflammatory reactivity

1994
- 1994-11-02 PL PL94314191A patent/PL314191A1/xx unknown
- 1994-11-02 JP JP7513400A patent/JPH09504792A/ja active Pending
- 1994-11-02 HU HU9601149A patent/HUT74275A/hu unknown
- 1994-11-02 CA CA002175457A patent/CA2175457A1/en not_active Abandoned
- 1994-11-02 EP EP95900514A patent/EP0726780A1/en not_active Withdrawn
- 1994-11-02 CZ CZ961226A patent/CZ122696A3/cs unknown
- 1994-11-02 WO PCT/US1994/012621 patent/WO1995012416A1/en not_active Ceased
- 1994-11-02 AU AU81316/94A patent/AU8131694A/en not_active Abandoned
1996
- 1996-04-30 NO NO961747A patent/NO961747L/no unknown
- 1996-05-31 LT LT96-079A patent/LT96079A/lt unknown

Also Published As

Publication number	Publication date
LT96079A (en)	1996-10-25
WO1995012416A1 (en)	1995-05-11
PL314191A1 (en)	1996-09-02
EP0726780A1 (en)	1996-08-21
AU8131694A (en)	1995-05-23
HUT74275A (en)	1996-11-28
NO961747L (no)	1996-07-02
JPH09504792A (ja)	1997-05-13
HU9601149D0 (en)	1996-06-28
NO961747D0 (no)	1996-04-30
CZ122696A3 (en)	1996-12-11

Legal Events

Date	Code	Title	Description
1998-11-02	FZDE	Discontinued

Publication	Publication Date	Title
Orth et al.	1983	Effect of synthetic ovine corticotropin-releasing factor. Dose response of plasma adrenocorticotropin and cortisol.
US5124314A (en)	1992-06-23	Pharmaceutical compositions containing amylin
US5374620A (en)	1994-12-20	Growth-promoting composition and its use
US5175145A (en)	1992-12-29	Treatment of diabetes mellitus with amylin agonists
US5112804A (en)	1992-05-12	Pharmaceutical composition and method of intranasal administration
US5597802A (en)	1997-01-28	Method of formulating IGF-I with growth hormone
JP2783825B2 (ja)	1998-08-06	腎臓疾患治療用医薬製剤
US20070197774A1 (en)	2007-08-23	Adrenocorticotropic hormone analogs and related methods
CN101084009B (zh)	2011-09-21	Gh促分泌素及其用途
CA2175457A1 (en)	1995-05-11	Treatment for rheumatoid arthritis
CA2142455A1 (en)	1994-03-03	Method for systemic treatment of catabolic conditions and systemic tissue injury
US20130096048A1 (en)	2013-04-18	Treatment of sepsis and septic shock using ghrelin and growth hormone
Konturek et al.	1972	Effect of vagotomy on pancreatic secretion evoked by endogenous and exogenous cholecystokinin and caerulein
JP3176051B2 (ja)	2001-06-11	避妊方法とその組成物
US20050032698A1 (en)	2005-02-10	Stabilized formulation of parathyroid hormone
US5700775A (en)	1997-12-23	Method and treatment composition for decreasing patient time in catabolic state after traumatic injury
Pappas et al.	1987	Corticotropin-releasing factor inhibits gastric emptying in dogs: studies on its mechanism of action
Rao et al.	1986	β‐Endorphin: intranasal administration increases the serum prolactin level in monkey
CN112138148A (zh)	2020-12-29	一种生长激素或其类似物的口服药物组合物
EP0672420A1 (en)	1995-09-20	Wound remedy
US6696414B2 (en)	2004-02-24	Use of growth hormone in low dose
JPS63243033A (ja)	1988-10-07	経鼻投与組成物
Dubreuil et al.	1988	Serum growth hormone release in response to a growth hormone-releasing factor analog during and after anesthesia in pigs
Wallace et al.	1996	Growth hormone treatment in adults with liver cirrhosis
Gazizova et al.	1995	The use of antiherpetic gamma-globulin in a complex treatment of duodenal ulcer patients